FDA temperature mapping in 2026: 5 questions answered

What does the FDA actually expect from your temperature mapping program in 2026? Recorded at Eupry's US office, this webinar works through five questions on FDA-compliant temperature mapping with Jakob Konradsen (Co-founder and Chief Quality Officer) and Devin Kelley (Head of US partnerships). FDA inspectors are increasingly citing the system around your mapping, not just a single data point that drifts out of range. The recurring theme: can you justify your decisions, act on tendencies before alarms fire, and show the logic running from your product to your process to your testing methodology? Jakob breaks down what inspectors flag now, how the FDA's risk-based approach differs from the EU, the real triggers for a re-mapping, why temperature-only studies get cited for missing humidity or CO₂ data, and how continuous mapping and monitoring changes the picture. Useful links: 🔗 Watch and learn more: https://eupry.com/temperature-mapping... 🔗 Temperature mapping guide: https://eupry.com/temperature-mapping/ 🔗 FDA 21 CFR Part 11 explained: https://eupry.com/regulations-tempera... Eupry provides integrated temperature compliance solutions for pharmaceutical, biotech, and healthcare logistics organizations. One platform for monitoring, mapping, calibration, and validation — replacing the complexity of managing 40+ vendors. Learn more: https://eupry.com Download the product catalog: https://eupry.com/product-catalog/ Follow Eupry: LinkedIn:   / eupry   #pharma #gmp #temperaturemapping